A detailed history of Jpmorgan Chase & CO transactions in Cara Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 74,857 shares of CARA stock, worth $21,708. This represents 0.0% of its overall portfolio holdings.

Number of Shares
74,857
Previous 34,040 119.91%
Holding current value
$21,708
Previous $30,000 36.67%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$0.24 - $0.92 $9,796 - $37,551
40,817 Added 119.91%
74,857 $19,000
Q1 2024

May 10, 2024

BUY
$0.52 - $1.05 $1,499 - $3,027
2,883 Added 9.25%
34,040 $30,000
Q4 2023

Feb 12, 2024

SELL
$0.6 - $1.65 $6,188 - $17,018
-10,314 Reduced 24.87%
31,157 $23,000
Q3 2023

Nov 14, 2023

BUY
$1.67 - $3.33 $641 - $1,278
384 Added 0.93%
41,471 $69,000
Q2 2023

Aug 11, 2023

SELL
$2.83 - $4.94 $99,349 - $173,423
-35,106 Reduced 46.08%
41,087 $116,000
Q1 2023

May 18, 2023

BUY
$4.89 - $12.27 $167,805 - $421,057
34,316 Added 81.94%
76,193 $374,000
Q1 2023

May 11, 2023

SELL
$4.89 - $12.27 $132,191 - $331,694
-27,033 Reduced 39.23%
41,877 $205,000
Q4 2022

Feb 13, 2023

SELL
$8.88 - $12.77 $2.49 Million - $3.58 Million
-279,965 Reduced 80.25%
68,910 $739,000
Q3 2022

Nov 14, 2022

SELL
$8.24 - $12.56 $80,521 - $122,736
-9,772 Reduced 2.72%
348,875 $3.27 Million
Q2 2022

Aug 11, 2022

BUY
$7.45 - $13.84 $442,753 - $822,511
59,430 Added 19.86%
358,647 $3.27 Million
Q1 2022

May 11, 2022

SELL
$9.94 - $12.65 $351,647 - $447,519
-35,377 Reduced 10.57%
299,217 $3.64 Million
Q4 2021

Feb 10, 2022

BUY
$11.99 - $18.14 $2.63 Million - $3.98 Million
219,470 Added 190.64%
334,594 $4.08 Million
Q3 2021

Nov 12, 2021

BUY
$11.55 - $16.06 $1.33 Million - $1.85 Million
115,124 New
115,124 $1.78 Million

Others Institutions Holding CARA

About Cara Therapeutics, Inc.


  • Ticker CARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,725,900
  • Market Cap $15.6M
  • Description
  • Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...
More about CARA
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.